Garfall, Alfred L.

Teclistamab in Relapsed or Refractory Multiple Myeloma

Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 1,269

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

Cohen, A. D., Garfall, A. L., Stadtmauer, E. A., Melenhorst, J. J., Lacey, S. F., Lancaster, E., Vogl, D. T., Weiss, B. M., Dengel, K., Nelson, A., et al. (2019) · Journal of Clinical Investigation

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 778

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

Garfall, A. L., Maus, M. V., Hwang, W.-T., Lacey, S. F., Mahnke, Y. D., Melenhorst, J. J., Zheng, Z., Vogl, D. T., Cohen, A. D., Weiss, B. M., et al. (2015) · New England Journal of Medicine

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 624

Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer

Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., Zabor, E. C., Brogi, E., & Joyce, J. A. (2011) · Genes & Development

Immune cells in cancerProtease and Inhibitor Mechanisms

Cited by 541

CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

Bange, E. M., Han, N. A., Wileyto, P., Kim, J. Y., Gouma, S., Robinson, J., Greenplate, A. R., Hwee, M. A., Porterfield, F., Owoyemi, O., et al. (2021) · Nature Medicine

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 519

Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., Slingerland, J. B., Beghi, S., Herrera, P. S., Giardina, P., et al. (2022) · Nature Medicine

CAR-T cell therapy researchGut microbiota and health

Cited by 349

Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis

Waxman, A. J., Clasen, S., Hwang, W.-T., Garfall, A., Vogl, D. T., Carver, J., O’Quinn, R., Cohen, A. D., Stadtmauer, E. A., Ky, B., et al. (2018) · JAMA Oncology

Chemotherapy-induced cardiotoxicity and mitigationMultiple Myeloma Research and Treatments

Cited by 286

Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma

Cornell, R. F., Ky, B., Weiss, B. M., Dahm, C. N., Gupta, D. K., Du, L., Carver, J. R., Cohen, A. D., Engelhardt, B. G., Garfall, A. L., et al. (2019) · Journal of Clinical Oncology

Chemotherapy-induced cardiotoxicity and mitigationMultiple Myeloma Research and Treatments

Cited by 198

Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy

Garfall, A. L., Cohen, A. D., Susanibar-Adaniya, S. P., Hwang, W.-T., Vogl, D. T., Waxman, A. J., Lacey, S. F., Gonzalez, V. E., Fraietta, J. A., Gupta, M., et al. (2023) · Blood Cancer Discovery

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 83

Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).

van de Donk, N. W. C. J., Moreau, P., Garfall, A. L., Bhutani, M., Oriol, A., Nooka, A. K., Martin, T. G., Rosiñol, L., Mateos, M.-V., Bahlis, N. J., et al. (2023) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 71

Clinical management of patients with relapsed/refractory multiple myeloma treated with talquetamab

Chari, A., Krishnan, A., Rasche, L., Ye, J. C., Garfall, A., Popat, R., Lipe, B., Qin, X., Campagna, M., Masterson, T., et al. (2024) · Clinical Lymphoma Myeloma and Leukemia

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 53

Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).

Moreau, P., Usmani, S. Z., van de Donk, N. W. C. J., Garfall, A. L., Delforge, M., Oriol Rocafiguera, A., Nooka, A. K., Rosiñol, L., Bahlis, N. J., Rodríguez-Otero, P., et al. (2022) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsStatistical Methods in Clinical Trials

Cited by 5